|
|
|
Volumn 2, Issue 4, 2004, Pages
|
|
NCCN makes changes to its guidelines for treating fever and neutropenia
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIBIOTIC AGENT;
ANTINEOPLASTIC AGENT;
CEFEPIME;
CEFTAZIDIME;
CILASTATIN PLUS IMIPENEM;
DALFOPRISTIN PLUS QUINUPRISTIN;
DAPTOMYCIN;
LINEZOLID;
MAXIPRIME;
MEROPENEM;
UNCLASSIFIED DRUG;
VANCOMYCIN;
ANAMNESIS;
BACTERICIDAL ACTIVITY;
BACTERIUM ISOLATE;
BLOOD CULTURE;
BODY TEMPERATURE;
CANCER PATIENT;
FEVER;
GRAM NEGATIVE BACTERIUM;
HEALTH CARE ORGANIZATION;
HIGH RISK PATIENT;
HUMAN;
LABORATORY TEST;
LEUKOCYTE COUNT;
MONOTHERAPY;
NEUTROPENIA;
NOTE;
OUTPATIENT CARE;
PATIENT MONITORING;
PHYSICAL EXAMINATION;
PRACTICE GUIDELINE;
PREDICTION;
PSEUDOMONAS AERUGINOSA;
RISK ASSESSMENT;
TREATMENT CONTRAINDICATION;
ANTI-BACTERIAL AGENTS;
ANTINEOPLASTIC AGENTS;
FEVER;
HUMANS;
NEOPLASMS;
NEUTROPENIA;
PRACTICE GUIDELINES;
UNITED STATES;
|
|
EID: 6944230796
PISSN: 15446794
EISSN: None
Source Type: Journal
DOI: None Document Type: Note |
|
Times cited : (4)
|
|
References (0)
|